Claims
- 1. A compound having anti-cancer activity comprising:
- 2. The compound of claim 1, wherein said compound has the formula:
- 3. The compound of claim 1, wherein said compound has the formula:
- 4. The compound of claim 1, wherein said compound has the formula:
- 5. A pharmaceutical composition having anti-cancer activity comprising a pharmaceutical carrier and an organic arsenical compound having the formula:
- 6. A method of treating a patient with cancer comprising of administering a composition comprising a therapeutically effective amount of a compound having the formula:
- 7. The method of claim 6, wherein said compound has the formula:
- 8. The method of claim 6, wherein said compound has the formula:
- 9. The method of claim 6, wherein said compound has the formula:
- 10. The method of claim 6, wherein said cancer comprises a solid tumor.
- 11. The method of claim 10, wherein said cancer is brain, lung, liver, spleen, kidney, lymph node, small intestine, pancreas, blood cells, bone, colon, stomach, breast, endometrium, prostate, testicle, ovary, central nervous system, skin, head and neck, esophagus, or bone marrow cancer.
- 12. The method of claim 6, wherein said cancer is a hematological cancer.
- 13. The method of claim 12, wherein said cancer is leukemia, lymphoma, multiple myeloma, myelodysplasia, myeloproliferative disease, or refractory anemia.
- 14. The method of claim 13, wherein said cancer is acute promyelocytic leukemia.
- 15. The method of claim 6, wherein said pharmaceutically effective amount is 0.1-1000 mg/kg.
- 16. The method of claim 15, wherein said pharmaceutically effective amount is 1-500 mg/kg.
- 17. The method of claim 16, wherein said pharmaceutically effective amount is 10-100 mg/kg.
- 18. The method of claim 6, wherein said compound is administered daily.
- 19. The method of claim 6, wherein said compound is administered by injection.
- 20. The method of claim 6, wherein an additional agent is administered to said patient.
- 21. The method of claim 20, wherein said additional agent is all-trans-retinoic acid, 9-cis retinoic acid, Am-80 or ascorbic acid.
Parent Case Info
[0001] The present application claims priority to co-pending provisional U.S. Application Serial No. 60/346,492 filed Jan. 7, 2002. The entire text of the above referenced application is incorporated herein by reference and without disclaimer.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60346492 |
Jan 2002 |
US |